Lemos-Pérez, G.; Barrese-Pérez, Y.; Chacón-Quintero, Y.; Uranga-Piña, R.; Avila-Albuerne, Y.; Figueroa-García, I.; Calderín-Marín, O.; Gómez-Vázquez, M.M.; Piñera-Martínez, M.; Chávez-Valdés, S.;
et al. Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial. Vaccines 2024, 12, 1001.
https://doi.org/10.3390/vaccines12091001
AMA Style
Lemos-Pérez G, Barrese-Pérez Y, Chacón-Quintero Y, Uranga-Piña R, Avila-Albuerne Y, Figueroa-García I, Calderín-Marín O, Gómez-Vázquez MM, Piñera-Martínez M, Chávez-Valdés S,
et al. Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial. Vaccines. 2024; 12(9):1001.
https://doi.org/10.3390/vaccines12091001
Chicago/Turabian Style
Lemos-Pérez, Gilda, Yinet Barrese-Pérez, Yahima Chacón-Quintero, Rolando Uranga-Piña, Yisel Avila-Albuerne, Iglermis Figueroa-García, Osaida Calderín-Marín, Martha M. Gómez-Vázquez, Marjoris Piñera-Martínez, Sheila Chávez-Valdés,
and et al. 2024. "Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial" Vaccines 12, no. 9: 1001.
https://doi.org/10.3390/vaccines12091001
APA Style
Lemos-Pérez, G., Barrese-Pérez, Y., Chacón-Quintero, Y., Uranga-Piña, R., Avila-Albuerne, Y., Figueroa-García, I., Calderín-Marín, O., Gómez-Vázquez, M. M., Piñera-Martínez, M., Chávez-Valdés, S., Martínez-Rosales, R., Ávila-Díaz, L., Vázquez-Arteaga, A., González-Formental, H., Freyre-Corrales, G., Coizeau-Rodríguez, E., Limonta-Fernández, M., Ayala-Avila, M., Martínez-Díaz, E.,
... Guillen, G.
(2024). Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial. Vaccines, 12(9), 1001.
https://doi.org/10.3390/vaccines12091001
